TYRA
Tyra Biosciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 12 ▼ 1 insider sell $263.0K at $32.87
- Mar 25 ▼ 1 insider sell $528.5K at $36.97
- Jun 17 Jones Trading initiates
- Jun 26 ▼ Nextech VI Oncology SCSP, a significant VC shareholder, filed a Form…
- Aug 4 ▼ Tyra Biosciences has amended its existing at-the-market (ATM) equity…
- Sep 9 to Sep 15 ▲ 2 days of insider buys: $200.0M by 2 insiders, avg $22.03
- Sep 9 ▲ Tyra Biosciences announced positive initial Phase 2 data for oral da…
- Sep 17 ▲ Two Tyra Biosciences insiders, including 10% owner RA Capital Manage…
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $200.0M at an average $22.03. 2 insiders sold $791.5K. Price is 9% below their cost.
- InstitutionsMIXED
Q3 2026: 15 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
19 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +4.3% to 9.90M shares. 15.3 days to cover, ≈14.4% of shares.
- TrendRANGE
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | DOUBLED | $18.1M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $7.2M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $6.6M |
| MORGAN STANLEY | TRIM | $4.5M |
| UBS Group AG | ADD | $3.9M |
| Walleye Capital LLC | TRIM | $2.1M |
| Jump Financial, LLC | TRIM | $1.9M |
| ALPS ADVISORS INC | ADD | $1.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +150%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Wedbush MAINTAIN | Outperform |
| Nov 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 22, 2026 | Oppenheimer REITERATE | Outperform |
| Sep 22, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 10, 2026 | Wedbush REITERATE | Outperform |
| Sep 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Rueb Yuliya Vice President, Finance (PAO) Sep 15, 2026 | AWARD | $26.7K |
Harris Todd President and CEO Sep 15, 2026 | AWARD | $7.9K |
Fuhrman Alan Chief Financial Officer Sep 15, 2026 | AWARD | $8.7K |
RA CAPITAL MANAGEMENT, L.P. Director Sep 15, 2026 | BUY | $200.0M |
Verjee Rehan Director Sep 9, 2026 | BUY | $20.0K |
Gulfo Adele M. Director May 28, 2026 | AWARD | 13,160 sh |
MORE ROBERT J Director May 28, 2026 | AWARD | 13,160 sh |
Rothenberg Stephen Michael Director May 28, 2026 | AWARD | 13,160 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 2 bullish · 2 bearish · 1 mixed · 8 neutral- NEUTRAL 8-KNov 10, 2026
Tyra Biosciences reported Q3 2026 net loss of $51.1M, wider than the $29.9M loss in Q3 2025…
Monitor upcoming regulatory engagement for Phase 3 adjuvant study design in IR NMIBC and initial BEACH301 safety sentinel cohort results, both expected in 2027. The $400M financing removes near-term…
- NEUTRAL SC 13G/AOct 27, 2026
BlackRock, Inc. filed an amendment to its Schedule 13G for Tyra Biosciences, reporting a 4.8%…
Monitor for any further 13G amendments or a potential conversion to a 13D if BlackRock's intent changes. The reduction below 5% removes the requirement for ongoing 13G filings, so future disclosures…
- NEUTRAL SC 13GSep 21, 2026
Biotechnology Value Fund (BVF) and related entities filed a Schedule 13G on September 21, 2026…
Monitor for any future conversion of this 13G to a 13D, which would signal activist intent. The large passive stake by a dedicated biotech fund signals conviction but no near-term catalyst.
- BULLISH CLUSTERSep 17, 2026
Two Tyra Biosciences insiders, including 10% owner RA Capital Management, made open-market…
A 10% owner deploying 61% of market cap into open-market stock is an extreme conviction signal. Watch for a near-term catalyst (data readout, partnership, or M&A) that RA Capital may be anticipating.
All TYRA filing & press-release reports (13)
- 8-K reportNov 10, 2026
- SC 13G/A reportOct 27, 2026
- SC 13G reportSep 21, 2026
- CLUSTER reportSep 17, 2026
- S-3ASR reportSep 14, 2026
- 8-K reportSep 9, 2026
- 424B5 reportAug 4, 2026
- 144 reportJun 26, 2026
- 8-K reportMay 13, 2026
- 3 reportApr 20, 2026
- DEFA14A reportApr 17, 2026
- 8-K reportApr 17, 2026
- 144 reportApr 13, 2026